Patents by Inventor Christian Oefner
Christian Oefner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10363284Abstract: ?-Hairpin peptidomimetics of the general formula cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Xaa6-DPro7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Xaa13-Xaa14-Xaa15-Pro16-), disulfide bond between Cys4 and Cys11, and pharmaceutically acceptable salts thereof, with Xaa3, Xaa6, Xaa8, Xaa13, Xaa14 and Xaa15 being amino acid residues of certain types which are defined in the description and the claims, have favorable pharmacological properties and can be used for preventing HIV infections in healthy individuals or for slowing and halting viral progression in infected patients; or where cancer is mediated or resulting from CXCR4 receptor activity; or where immunological diseases are mediated or resulting from CXCR4 receptor activity; or for treating immunosuppression; or during apheresis collections of peripheral blood stem cells and/or as agents to induce mobilization of stem cells to regulate tissue repair. These peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.Type: GrantFiled: February 27, 2017Date of Patent: July 30, 2019Assignee: POLYPHOR AGInventors: Frank Otto Gombert, Daniel Obrecht, Alexander Lederer, Johann Zimmermann, Christian Oefner
-
Publication number: 20170165319Abstract: ?-Hairpin peptidomimetics of the general formula cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Xaa6-DPro7-Xaa8-Arg9-Tyr12-Xaa13Xaa14-Xaa15-Pro16-), disulfide bond between Cys4 and Cys11, and pharmaceutically acceptable salts thereof, with Xaa3, Xaa6, Xaa8, Xaa13, Xaa14 and Xaa15 being amino acid residues of certain types which are defined in the description and the claims, have favorable pharmacological properties and can be used for preventing HIV infections in healthy individuals or for slowing and halting viral progression in infected patients; or where cancer is mediated or resulting from CXCR4 receptor activity; or where immunological diseases are mediated or resulting from CXCR4 receptor activity; or for treating immunosuppression; or during apheresis collections of peripheral blood stem cells and/or as agents to induce mobilization of stem cells to regulate tissue repair. These peptidomimetics can be manufactured by a process which is based on a mixed solid-and solution phase synthetic strategy.Type: ApplicationFiled: February 27, 2017Publication date: June 15, 2017Applicant: POLYPHOR AGInventors: Frank Otto GOMBERT, Daniel OBRECHT, Alexander LEDERER, Johann ZIMMERMANN, Christian OEFNER
-
Patent number: 9617308Abstract: ?-Hairpin peptidomimetics of the general formula cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Xaa6-DPro7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Xaa13-Xaa14-Xaa15-Pro16-), disulfide bond between Cys4 and Cys11, and pharmaceutically acceptable salts thereof, with Xaa3, Xaa6, Xaa8 Xaa13, Xaa14 and Xaa15 being amino acid residues of certain types which are defined in the description and the claims, have favorable pharmacological properties and can be used for preventing HIV infections in healthy individuals or for slowing and halting viral progression in infected patients; or where cancer is mediated or resulting from CXCR4 receptor activity; or where immunological diseases are mediated or resulting from CXCR4 receptor activity; or for treating immunosuppression; or during apheresis collections of peripheral blood stem cells and/or as agents to induce mobilization of stem cells to regulate tissue repair. These peptidomimetics can be manufactured by a process which is based on a mixed solid-and solution phase synthetic strategy.Type: GrantFiled: June 6, 2012Date of Patent: April 11, 2017Assignee: POLYPHOR AGInventors: Frank Otto Gombert, Daniel Obrecht, Alexander Lederer, Johann Zimmermann, Christian Oefner
-
Publication number: 20150218219Abstract: ?-Hairpin peptidomimetics of the general formula cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Xaa6-DPro7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Xaa13-Xaa14-Xaa15-Pro16-), disulfide bond between Cys4 and Cys11, and pharmaceutically acceptable salts thereof, with Xaa3, Xaa6, Xaa8 Xaa13, Xaa14 and Xaa15 being amino acid residues of certain types which are defined in the description and the claims, have favorable pharmacological properties and can be used for preventing HIV infections in healthy individuals or for slowing and halting viral progression in infected patients; or where cancer is mediated or resulting from CXCR4 receptor activity; or where immunological diseases are mediated or resulting from CXCR4 receptor activity; or for treating immunosuppression; or during apheresis collections of peripheral blood stem cells and/or as agents to induce mobilization of stem cells to regulate tissue repair. These peptidomimetics can be manufactured by a process which is based on a mixed solid-and solution phase synthetic strategy.Type: ApplicationFiled: June 6, 2012Publication date: August 6, 2015Applicant: POLYPHOR AGInventors: Frank Otto Gombert, Daniel Obrecht, Alexander Lederer, Johann Zimmermann, Christian Oefner
-
Publication number: 20060084614Abstract: The present invention relates to new compounds of formula (I): These compounds are very effective factor VIIa inhibitors and are therefore of interest in the treatment and/or prevention of thromboses, stroke, heart attack, inflammation, arteriosclerosis and tumour conditions.Type: ApplicationFiled: January 5, 2004Publication date: April 20, 2006Inventors: Robert Eckl, Lutz Weber, Christian Oefner
-
Publication number: 20060046978Abstract: This invention relates to novel compounds, compositions containing the compounds, that inhibit dipeptidyl peptidase (especially DPP-IV) and neprilysin (NEP, neutral endopeptidase) as well as dipeptidyl peptidase (especially DPP-IV) and angiotensin converting enzyme (ACE) and/or dipeptidyl Peptidase (especially DPP-IV) and vasopeptidases (especially ACE and NEP). These compounds and pharmaceutical compositions thereof are useful for the treatment as well as the prevention of type 2 diabetes mellitus.Type: ApplicationFiled: August 31, 2004Publication date: March 2, 2006Applicant: Morphochem AGInventors: Sabine Pierau, Christian Oefner, Glenn Dale
-
Publication number: 20050049283Abstract: The present invention related to compounds of formula (I): or pharmaceutically acceptable salts, hydrates or pharmaceutically acceptable formulations thereof. Those compounds can be used in inhibiting factor Xa and in the prevention and/or treatment of thromboembolic conditions.Type: ApplicationFiled: January 31, 2003Publication date: March 3, 2005Inventors: Robert Eckl, Silke Schabbert, Thilo Fuchs, Lutz Weber, Christian Oefner
-
Patent number: 6150526Abstract: Piperidine derivatives, their manufacture and use as medicaments, are disclosed. The invention is concerned with the piperidine derivatives of general formula I ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, Q, X, Z, m and n are as described herein.Type: GrantFiled: December 7, 1999Date of Patent: November 21, 2000Assignee: Hoffmann-La Roche Inc.Inventors: Alfred Binggeli, Volker Breu, Daniel Bur, Walter Fischli, Rolf Guller, Georges Hirth, Hans-Peter Marki, Marcel Muller, Christian Oefner, Heinz Stadler, Eric Vieira, Maurice Wilhelm, Wolfgang Wostl
-
Patent number: 6051712Abstract: Novel piperidine derivatives, their manufacture and use as medicaments, are disclosed. The invention is concerned with the novel piperidine derivatives of general formula I ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, Q, X, Z, m and n are as described herein.Type: GrantFiled: February 22, 1999Date of Patent: April 18, 2000Assignee: Hoffmann-La Roche Inc.Inventors: Alfred Binggeli, Volker Breu, Daniel Bur, Walter Fischli, Rolf Guller, Georges Hirth, Hans-Peter Marki, Marcel Muller, Christian Oefner, Heinz Stadler, Eric Vieira, Maurice Wilhelm, Wolfgang Wostl